Compare NVEC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | FULC |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.4M | 467.8M |
| IPO Year | 1995 | 2019 |
| Metric | NVEC | FULC |
|---|---|---|
| Price | $119.36 | $3.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 250.5K | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-27-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ 0.96 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $26,331,218.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $95.41 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $57.21 | $2.83 |
| 52 Week High | $135.00 | $15.74 |
| Indicator | NVEC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 51.59 |
| Support Level | $81.02 | $3.44 |
| Resistance Level | $135.00 | $4.02 |
| Average True Range (ATR) | 9.52 | 0.14 |
| MACD | 1.84 | 0.05 |
| Stochastic Oscillator | 85.39 | 82.95 |
NVE Corp is engaged in developing and selling devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.